144 related articles for article (PubMed ID: 10903326)
1. Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice.
Ishigaki Y; Oikawa S; Suzuki T; Usui S; Magoori K; Kim DH; Suzuki H; Sasaki J; Sasano H; Okazaki M; Toyota T; Saito T; Yamamoto TT
J Biol Chem; 2000 Oct; 275(40):31269-73. PubMed ID: 10903326
[TBL] [Abstract][Full Text] [Related]
2. Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy.
Saito T; Ishigaki Y; Oikawa S; Yamamoto TT
Trends Cardiovasc Med; 2002 Feb; 12(2):67-70. PubMed ID: 11852253
[TBL] [Abstract][Full Text] [Related]
3. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy.
Hoffmann MM; Scharnagl H; Panagiotou E; Banghard WT; Wieland H; März W
J Am Soc Nephrol; 2001 Mar; 12(3):524-530. PubMed ID: 11181800
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice.
Ishimura A; Watanabe M; Nakashima H; Ito K; Miyake K; Mochizuki S; Ishigaki Y; Saito T
Clin Exp Nephrol; 2009 Oct; 13(5):430-437. PubMed ID: 19459027
[TBL] [Abstract][Full Text] [Related]
5. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases.
Saito T; Matsunaga A; Oikawa S
Am J Kidney Dis; 2006 Feb; 47(2):199-211. PubMed ID: 16431249
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein glomerulopathy induced by ApoE Kyoto mutation in ApoE-deficient mice.
Wu H; Yang J; Liu YQ; Lei S; Yang M; Yang Z; Yang Y; Hu Z
J Transl Med; 2021 Mar; 19(1):97. PubMed ID: 33663537
[TBL] [Abstract][Full Text] [Related]
7. A founder haplotype of APOE-Sendai mutation associated with lipoprotein glomerulopathy.
Toyota K; Hashimoto T; Ogino D; Matsunaga A; Ito M; Masakane I; Degawa N; Sato H; Shirai S; Umetsu K; Tamiya G; Saito T; Hayasaka K
J Hum Genet; 2013 May; 58(5):254-8. PubMed ID: 23407349
[TBL] [Abstract][Full Text] [Related]
8. Plasma level and genetic variation of apolipoprotein E in patients with lipoprotein glomerulopathy.
Zhang B; Liu ZH; Zeng CH; Zheng JM; Chen HP; Zhou H; Li LS
Chin Med J (Engl); 2005 Apr; 118(7):555-60. PubMed ID: 15820086
[TBL] [Abstract][Full Text] [Related]
9. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy.
Matsunaga A; Sasaki J; Komatsu T; Kanatsu K; Tsuji E; Moriyama K; Koga T; Arakawa K; Oikawa S; Saito T; Kita T; Doi T
Kidney Int; 1999 Aug; 56(2):421-7. PubMed ID: 10432380
[TBL] [Abstract][Full Text] [Related]
10. Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor.
van Dijk KW; van Vlijmen BJ; van der Zee A; van't Hof B; van der Boom H; Kobayashi K; Chan L; Havekes LM; Hofker MH
Arterioscler Thromb Vasc Biol; 1998 Jan; 18(1):7-12. PubMed ID: 9445249
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features.
Saito T; Oikawa S; Sato H; Sato T; Ito S; Sasaki J
Kidney Int Suppl; 1999 Jul; 71():S37-41. PubMed ID: 10412734
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E-related glomerular disorders.
Saito T; Matsunaga A; Fukunaga M; Nagahama K; Hara S; Muso E
Kidney Int; 2020 Feb; 97(2):279-288. PubMed ID: 31874799
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and genetic characteristics in Chinese patients with lipoprotein glomerulopathy.
Zhang B; Liu ZH; Zeng CH; Zheng JM; Chen HP; Li LS
J Nephrol; 2008; 21(1):110-7. PubMed ID: 18264944
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein glomerulopathy associated with the Osaka/Kurashiki APOE variant: two cases identified in Latin America.
da Silveira-Neto JN; de Oliveira Ahn GJ; de Menezes Neves PDM; Baptista VAF; de Almeida Araújo S; Wanderley DC; Watanabe A; Watanabe EH; Murai NM; Bertollo EMG; Vieira-Neto OM; Dantas M; de Antônio SR; Costa RS; Baptista MASF; Moysés-Neto M; Onuchic LF
Diagn Pathol; 2021 Jul; 16(1):65. PubMed ID: 34311745
[TBL] [Abstract][Full Text] [Related]
15. Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy.
Luo B; Huang F; Liu Q; Li X; Chen W; Zhou SF; Yu X
Am J Nephrol; 2008; 28(2):347-53. PubMed ID: 18046082
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia.
Matsunaga A; Saito T
Clin Exp Nephrol; 2014 Apr; 18(2):220-4. PubMed ID: 24570178
[TBL] [Abstract][Full Text] [Related]
17. The Novel Apolipoprotein E Mutation ApoE Chengdu (c.518T＞C, p.L173P) in a Chinese Patient with Lipoprotein Glomerulopathy.
Wu H; Yang Y; Hu Z
J Atheroscler Thromb; 2018 Aug; 25(8):733-740. PubMed ID: 29398675
[TBL] [Abstract][Full Text] [Related]
18. Clinical and genetic analysis of lipoprotein glomerulopathy patients caused by APOE mutations.
Yang M; Weng Q; Pan X; Hussain HMJ; Yu S; Xu J; Yu X; Liu Y; Jin Y; Zhang C; Li X; Ren H; Chen N; Xie J
Mol Genet Genomic Med; 2020 Aug; 8(8):e1281. PubMed ID: 32441489
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein glomerulopathy with markedly increased arterial stiffness successfully treated with a combination of fenofibrate and losartan: a case report.
Kato J; Okonogi H; Kanzaki G; Katsumata H; Nakada Y; Sagasaki M; Komine K; Ito K; Saito T; Matsunaga A; Tokutou K; Honda K; Tsuboi N; Yokoo T
BMC Nephrol; 2024 May; 25(1):171. PubMed ID: 38769490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
